|Systematic (IUPAC) name|
|Trade names||Camcolit (UK),
|Pregnancy cat.||D (AU) D (US)|
|Legal status||Prescription Only (S4) (AU) ℞-only (CA) POM (UK) ℞-only (US)|
|Bioavailability||depends on formulation|
36 hours (elderly),
17.9 hours (children),
2.43 days (chronic treatment)
|Mol. mass||6.941 g/mol|
Lithium compounds are used as a psychiatric medication. A number of salts of lithium are used as mood-stabilizing drugs, primarily in the treatment of bipolar disorder, where they have a role in the treatment of depression and particularly of mania, both acutely and in the long term. As a mood stabilizer, lithium is probably more effective in preventing mania than depression, and reduces the risk of suicide in people with bipolar. In depression alone (unipolar disorder), lithium can be used to augment other antidepressants. Lithium carbonate (Li
3), sold under several trade names, is the most commonly prescribed, while lithium citrate (Li
7) is also used in conventional pharmacological treatments. Lithium orotate (C
4), has been presented as an alternative. Lithium bromide and lithium chloride have been used in the past, however they fell out of use in the 1940s when it was discovered they were toxic. Many other lithium salts and compounds exist, such as lithium fluoride and lithium iodide, but they are presumed to be toxic substances and have never been evaluated for pharmacological effects.
Upon ingestion, lithium becomes widely distributed in the central nervous system and interacts with a number of neurotransmitters and receptors, decreasing norepinephrine (noradrenaline) release and increasing serotonin synthesis. The specific biochemical mechanism of lithium action in mania is unknown.
Lithium is used primarily for bipolar disorder. It is sometimes used when other treatments are not effective in a number of other conditions include: major depression, schizophrenia, and some psychiatric disorders in children. In mood disorders, of which bipolar is one, it decreases the risk of suicide. This benefit is not seen with other medications.
Lithium treatment was previously considered to be unsuitable for children; however, more recent studies show its effectiveness for treatment of early-onset bipolar disorder in children as young as eight. The required dosage is slightly less than the toxic level, requiring blood levels of lithium to be monitored closely during treatment. High doses of haloperidol, fluphenazine, or flupenthixol may be hazardous when used with lithium; irreversible toxic encephalopathy has been reported. A limited amount of evidence suggests lithium may contribute to treatment of substance abuse for some people with dual-disorder.
Two forms of low dose lithium supplementation, lithium aspartate and lithium orotate, may protect the brain and encourage the growth of gray matter in the cerebral cortex and prevent and slow the progression of Alzheimer's disease, senile dementia and Parkinson's disease.[unreliable medical source?]
Those who use lithium should receive regular serum level tests and should monitor thyroid and kidney function for abnormalities, as it interferes with the regulation of sodium and water levels in the body, and can cause dehydration. Dehydration, which is compounded by heat, can result in increasing lithium levels. The dehydration is due to lithium inhibition of the action of antidiuretic hormone, which normally enables the kidney to reabsorb water from urine. This causes an inability to concentrate urine, leading to consequent loss of body water and thirst.
Lithium concentrations in whole blood, plasma, serum or urine may be measured using instrumental techniques as a guide to therapy, to confirm the diagnosis in potential poisoning victims or to assist in the forensic investigation in a case of fatal overdosage. Serum lithium concentrations are usually in the 0.5–1.3 mmol/l range in well-controlled people, but may increase to 1.8–2.5 mmol/l in those who accumulate the drug over time and to 3–10 mmol/l in acute overdose.
Lithium salts have a narrow therapeutic/toxic ratio, so should not be prescribed unless facilities for monitoring plasma concentrations are available. People should be carefully selected. Doses are adjusted to achieve plasma concentrations of 0.4 to 1.2 mmol Li+
/l (lower end of the range for maintenance therapy and the elderly, higher end for children) on samples taken 12 hours after the preceding dose.
- Very Common (>10% incidence) adverse effects of lithium include
- Leukocytosis — elevated white blood cell count
- Polyuria/polydypsia — increased thirst and urination
- Dry mouth
- Hand tremor (usually transient but it can persist in some people)
- Decreased memory
- Muscle weakness (usually transient, but can persist in some)
- ECG changes — usually benign changes in T waves.
- Nausea (usually transient, but can persist in some)
- Vomiting (usually transient, but can persist in some)
- Diarrhea (usually transient, but can persist in some)
- Constipation (usually transient, but can persist in some)
- Muscle twitch
- Hyperreflexia — overresponsive reflexes
- Common (1-10%) adverse effects include
- Extrapyramidal side effects — movement-related problems such as muscle rigidity, parkinsonism, dystonia, etc.
- Euthyroid goitre — i.e. the formation of a goitre despite normal thyroid functioning
- Hypothyroidism — a deficiency of thyroid hormone.
- Hair loss/hair thinning
- Rare/Uncommon (<1%) adverse effects include
- Renal (kidney) toxicity which may lead to chronic kidney failure
- Renal interstitial fibrosis
- Erythema multiforme — a potentially fatal skin reaction
- Brugada syndrome — a potentially fatal abnormality in the electrical activity of the heart.
- Sinus node dysfunction
- Transient reduction in peripheral circulation as a whole
- Pseudotumor cerebri
- Increased intracranial pressure and papilledema
- Myasthenia gravis — an autoimmune condition where the body's own defences attack the neuromuscular junction — the gap across which the nerves communicate with the muscles — leading to muscle weakness.
- Hyperthyroidism — elevated blood concentrations of thyroid hormones.
- Hypercalcaemia — elevated blood levels of calcium.
- Hypermagnesaemia — elevated blood levels of magnesium.
- Hyperparathyroidism — elevated blood levels of parathyroid hormone.
- Unknown frequency adverse effects include
- Sexual dysfunction including impotence, vaginal dryness, erectile dysfunction, etc.
- Abdominal pain
- Glycosuria — glucose (blood sugar) in the urine
- Decreased creatinine clearance — a sign of impaired kidney function
- Albuminuria — protein in the urine another sign of impaired kidney function.
- Oliguria — low urine output although excess urine output is more likely.
- Changes in taste
- Slurred speech
- Hypotension — low blood pressure.
- Bradycardia — low heart rate.
- Nystagmus — involuntary eye movements that can interfere with vision.
- Weight gain or loss (gain more common with prolonged treatment)
According to an Australian study, "The incidence of hypothyroidism is six-fold higher in people on lithium as compared to the general population. Hypothyroidism in turn increases the likelihood of developing clinical depression." 
Lithium is known to be responsible for 1–2 kg of weight gain. Weight gain may be a source of low self-esteem for the clinically depressed. Because lithium competes with the receptors for the antidiuretic hormone in the kidney, it increases water output into the urine, a condition called nephrogenic diabetes insipidus. Clearance of lithium by the kidneys is usually successful with certain diuretic medications, including amiloride and triamterene. It increases the appetite and thirst ("polydypsia") and reduces the activity of thyroid hormone (hypothyroidism). The latter can be corrected by treatment with thyroxine. Lithium is also believed to permanently affect renal function, although this does not appear to be common.
Most side effects of lithium are dose-dependent. The lowest effective dose is used to limit the risk of side effects.
Lithium is also a teratogen, causing birth defects in a small number of newborn babies. Case reports and several retrospective studies have demonstrated possible increases in the rate of a congenital heart defect known as Ebstein's anomaly, if taken during a woman's pregnancy. As a consequence, fetal echocardiography is routinely performed in pregnant women taking lithium to exclude the possibility of cardiac anomalies. Lamotrigine seems to be a possible alternative to lithium in pregnant women. Gabapentin and clonazepam are also indicated as antipanic medications during the childbearing years and during pregnancy. Valproic acid and carbamazepine also tend to be associated with teratogenicity.
Dehydration in people taking lithium salts can be very hazardous, especially when combined with lithium induced nephrogenic diabetes insipidus with polyuria. Such situations include preoperative fluid regimen or other fluid inaccessibility, warm weather conditions, sporting events, and hiking.
Another danger is that rapid hydration may very quickly produce hyponatremia with its danger of toxic lithium concentrations in plasma.
Lithium concentrations are known to be increased with concurrent use of diuretics — especially loop diuretics (such as furosemide) and thiazides — and non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and aspirin. Lithium is also known to be a potential precipitant of serotonin syndrome in people concurrently on serotonergic medications such as antidepressants, buspirone and certain opioids (e.g. pethidine [meperidine in the US], tramadol, oxycodone, fentanyl, etc.). Lithium co-treatment is also a risk factor for neuroleptic malignant syndrome in people on antipsychotics and other antidopaminergic medications.
Lithium toxicity may occur in persons taking excessive amounts either accidentally or intentionally on an acute basis or in people who accumulate high levels during ongoing chronic therapy. The manifestations include nausea, emesis, diarrhea, asthenia, ataxia, confusion, lethargy, polyuria, seizures and coma. Other toxic effects of lithium include coarse tremor, muscle twitching, convulsions and renal failure. People who survive a poisoning episode may develop persistent neurotoxicity. Several authors have described a "Syndrome of Irreversible Lithium-Effected Neurotoxicity" (SILENT), associated with episodes of acute lithium toxicity or long-term treatment within the appropriate dosage range. Symptoms are said to include cerebellar dysfunction.
Overdosage, usually with plasma concentrations over 1.5 mmol Li+
/l, may be fatal, and toxic effects include tremor, ataxia, dysarthria, nystagmus, renal impairment, confusion, and convulsions. If these potentially hazardous signs occur, treatment should be stopped, plasma lithium concentrations redetermined, and steps taken to reverse lithium toxicity.
Lithium toxicity is compounded by sodium depletion. Concurrent use of diuretics that inhibit the uptake of sodium by the distal tubule (e.g. thiazides) is hazardous and should be avoided because this can cause increased resorption of lithium in the proximal convoluted tubule, leading to elevated, potentially toxic levels. In mild cases, withdrawal of lithium and administration of generous amounts of sodium and fluid will reverse the toxicity. Plasma concentrations in excess of 2.5 mmol Li+
/l are usually associated with serious toxicity requiring emergency treatment. When toxic concentrations are reached, there may be a delay of one or two days before maximum toxicity occurs.
In long-term use, therapeutic concentrations of lithium have been thought to cause histological and functional changes in the kidney. The significance of such changes is not clear, but is of sufficient concern to discourage long-term use of lithium unless it is definitely indicated. Doctors may change a bipolar patient's medication from lithium to another mood-stabilizing drug, such as valproate(Depakote), if problems with the kidneys arise. An important potential consequence of long-term lithium use is the development of renal diabetes insipidus (inability to concentrate urine). Patients should therefore be maintained on lithium treatment after three to five years only if, on assessment, benefit persists. Conventional and sustained-release tablets are available. Preparations vary widely in bioavailability, and a change in the formulation used requires the same precautions as initiation of treatment. There are few reasons to prefer any one simple salt of lithium; the carbonate has been the more widely used, but the citrate is also available.
Mechanism of action
The specific biochemical mechanism of lithium action in mania is unknown.
Recent research suggests three different mechanisms which may or may not act together to deliver the mood-stabilizing effect of this ion. The excitatory neurotransmitter glutamate could be involved in the effect of lithium as other mood stabilizers, such as valproate and lamotrigine, exert influence over glutamate, suggesting a possible biological explanation for mania. The other mechanisms by which lithium might help to regulate mood include the alteration of gene expression.
Lithium may also increase the release of serotonin by neurons in the brain. In vitro studies performed on serotonergic neurons from rat raphe nuclei have shown that when these neurons are treated with lithium, serotonin release is enhanced during a depolarization compared to no lithium treatment and the same depolarization.
An unrelated mechanism of action has been proposed in which lithium deactivates the GSK3β enzyme. This enzyme normally phosphorylates the Rev-Erbα transcription factor protein stabilizing it against degradation. Rev-Erbα in turn represses BMAL1, a component of the circadian clock. Hence, lithium by inhibiting GSK3β causes the degradation of Rev-Erbα and increases the expression of BMAL which damps the circadian clock. Through this mechanism, lithium is able to block the resetting of the "master clock" inside the brain; as a result, the body's natural cycle is disrupted. When the cycle is disrupted, the routine schedules of many functions (metabolism, sleep, body temperature) are disturbed. Lithium may thus restore normal brain function after it is disrupted in some people.
Several authors proposed that pAp-phosphatase could be one of the therapeutic targets of lithium. This hypothesis was supported by the low Ki of lithium for human pAp-phosphatase compatible within the range of therapeutic concentrations of lithium in the plasma of people (0.8–1 mM). Importantly, the Ki of human pAp-phosphatase is ten times lower than that of GSK3β (glycogen synthase kinase 3β). Inhibition of pAp-phosphatase by lithium leads to increased levels of pAp (3′-5′ phosphoadenosine phosphate), which was shown to inhibit PARP-1
Another mechanism proposed in 2007 is that lithium may interact with nitric oxide (NO) signalling pathway in the central nervous system, which plays a crucial role in the neural plasticity. The NO system could be involved in the antidepressant effect of lithium in the Porsolt forced swimming test in mice. It was also reported that NMDA receptor blockage augments antidepressant-like effects of lithium in the mouse forced swimming test, indicating the possible involvement of NMDA receptor/NO signaling in the action of lithium in this animal model of learned helplessness.
Lithium treatment has been found to inhibit the enzyme inositol monophosphatase, leading to higher levels of inositol triphosphate. This effect was enhanced further with an inositol triphosphate reuptake inhibitor. Inositol disruptions have been linked to memory impairment and depression.
Lithium was first used in the 19th century as a treatment for gout after scientists discovered, at least in the laboratory, lithium could dissolve uric acid crystals isolated from the kidneys. The levels of lithium needed to dissolve urate in the body, however, were toxic. Because of prevalent theories linking excess uric acid to a range of disorders, including depressive and manic disorders, Carl Lange in Denmark and William Alexander Hammond in New York used lithium to treat mania from the 1870s onwards. By the turn of the 20th century, as theory regarding mood disorders evolved and so-called "brain gout" disappeared as a medical entity, the use of lithium in psychiatry was largely abandoned. Some suggest that the pharmaceutical industry was reluctant to invest in a drug that could not be patented however a number of lithium preparations were yet produced for the control of renal calculi and ‘‘uric acid diathesis.’’. As accumulating knowledge indicated a role for excess sodium intake in hypertension and heart disease, lithium salts were prescribed to patients for use as a replacement for dietary table salt (sodium chloride). This practice was discontinued in 1949 when reports of side effects and deaths were published, leading to a ban of lithium sales.
The use of lithium salts to treat mania was rediscovered by the Australian psychiatrist John Cade in 1949. Cade was injecting rodents with urine extracts taken from schizophrenic patients, in an attempt to isolate a metabolic compound which might be causing mental symptoms. Since uric acid in gout was known to be psychoactive (adenosine receptors on neurons are stimulated by it; caffeine blocks them), Cade needed soluble urate for a control. He used lithium urate, already known to be the most soluble urate compound, and observed it caused the rodents to be tranquilized. Cade traced the effect to the lithium ion itself. Soon, Cade proposed lithium salts as tranquilizers, and soon succeeded in controlling mania in chronically hospitalized patients with them. This was one of the first successful applications of a drug to treat mental illness, and it opened the door for the development of medicines for other mental problems in the next decades.
The rest of the world was slow to adopt this treatment, largely because of deaths which resulted from even relatively minor overdosing, including those reported from use of lithium chloride as a substitute for table salt. Largely through the research and other efforts of Denmark's Mogens Schou and Paul Baastrup in Europe, and Samuel Gershon and Baron Shopsin in the U.S., this resistance was slowly overcome. The application of lithium in manic illness was approved by the United States Food and Drug Administration in 1970. In 1974, this application was extended to its use as a preventive agent for manic-depressive illness.
Lithium has become a part of Western popular culture. Characters in Pi, Premonition, Stardust Memories, American Psycho, Garden State, and An Unmarried Woman all take lithium. Sirius XM Satellite Radio in North America has a 1990s alternative rock station called Lithium, and several songs refer to the use of lithium as a mood stabilizer. These include: "Lithium Lips" by Mac Lethal, "Equilibrium met Lithium" by South African artist Koos Kombuis, "Lithium" by Evanescence, "Lithium" by Nirvana, "Lithium and a Lover" by Sirenia, "Lithium Sunset", from the album Mercury Falling by Sting, and "Lithium" by Thin White Rope.
Use in 7 Up
As with cocaine in Coca-Cola, lithium was widely marketed as one of a number of patent medicine products popular in the late-19th and early-20th centuries, and was the medicinal ingredient of a refreshment beverage. Charles Leiper Grigg, who launched his St. Louis-based company The Howdy Corporation, invented a formula for a lemon-lime soft drink in 1920. The product, originally named "Bib-Label Lithiated Lemon-Lime Soda", was launched two weeks before the Wall Street Crash of 1929. It contained the mood stabilizer lithium citrate, and was one of a number of patent medicine products popular in the late-19th and early-20th centuries. Its name was soon changed to 7 Up; all American beverage makers were forced to remove lithium in 1948. Despite the 1948 ban, the 13 July 1950 Painesville Telegraph has an advertisement for a lithiated lemon beverage on page 28.
There is tentative evidence that lithium may prevent Alzheimer's disease and may change disease progress in those with early symptoms. In the neurodegenerative disease amyotrophic lateral sclerosis (ALS) it has failed to produce positive results.
- Truven Health Analytics, Inc. DrugPoint® System (Internet) [cited 7 October 2013]. Greenwood Village, CO: Thomsen Healthcare; 2013.
- Baldessarini, Ross J; Tondo, Leonardo; Davis, Paula; Pompili, Maurizio; Goodwin, Frederick K; Hennen, John (2006). "Decreased risk of suicides and attempts during long-term lithium treatment: A meta-analytic review". Bipolar Disorders 8 (5p2): 625–39. doi:10.1111/j.1399-5618.2006.00344.x. PMID 17042835.
- Nieper HA (1973). "The clinical applications of lithium orotate. A two years study". Agressologie. 14 (6): 407–11. PMID 4607169.
- "Lithium salts". The American Society of Health-System Pharmacists. Retrieved 24 Sep 2013.
- Cipriani, A.; Hawton, K.; Stockton, S.; Geddes, JR. (2013). "Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis.". BMJ 346: f3646. doi:10.1136/bmj.f3646. PMID 23814104.
- Müller-Oerlinghausen, B; Berghöfer, A; Ahrens, B (2003). "The Antisuicidal and Mortality-Reducing Effect of Lithium Prophylaxis: Consequences for Guidelines in Clinical Psychiatry". Canadian Journal of Psychiatry 48 (7): 433–9. PMID 12971012.
- Kovacsics, Colleen E.; Gottesman, Irving I.; Gould, Todd D. (2009). "Lithium's Antisuicidal Efficacy: Elucidation of Neurobiological Targets Using Endophenotype Strategies". Annual Review of Pharmacology and Toxicology 49: 175–198. doi:10.1146/annurev.pharmtox.011008.145557. PMID 18834309.
- Semple, David "Oxford Hand Book of Psychiatry" Oxford Press. 2005.[page needed]
- Case reports: (Sandyk, R.; Hurwitz, M. D. (1983). "Toxic irreversible encephalopathy induced by lithium carbonate and haloperidol. A report of 2 cases". South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 64 (22): 875–876. PMID 6415823.)(Gille, M.; Ghariani, S.; Piéret, F.; Delbecq, J.; Depré, A.; Saussu, F.; De Barsy, T. (1997). "Acute encephalomyopathy and persistent cerebellar syndrome after lithium salt and haloperidol poisoning". Revue neurologique 153 (4): 268–270. PMID 9296146.)
- Rosenberg, J.; Salzman, C. (2007). "Update: New uses for lithium and anticonvulsants". CNS spectrums 12 (11): 831–841. PMID 17984856.
- Frye, M. A.; Salloum, I. M. (2006). "Bipolar disorder and comorbid alcoholism: Prevalence rate and treatment considerations". Bipolar Disorders 8 (6): 677–685. doi:10.1111/j.1399-5618.2006.00370.x. PMID 17156154.
- Vornik, L.; Brown, E. (2006). "Management of comorbid bipolar disorder and substance abuse". The Journal of clinical psychiatry. 67 Suppl 7: 24–30. PMID 16961421.
- Ohgami, H; Terao, T; Shiotsuki, I; Ishii, N; Iwata, N (2009). "Lithium levels in drinking water and risk of suicide". The British journal of psychiatry : the journal of mental science 194 (5): 464–5; discussion 446. doi:10.1192/bjp.bp.108.055798. PMID 19407280.
- Gonzalez, R; Bernstein, I; Suppes, T (2008). "An investigation of water lithium concentrations and rates of violent acts in 11 Texas counties: Can an association be easily shown?". The Journal of clinical psychiatry 69 (2): 325–6. doi:10.4088/jcp.v69n0221a. PMID 18363457.
- Healy D. 2005. Psychiatric Drugs Explained. 4th ed. Churchhill Livingstone: London.[page needed]
- Amdisen A. (1978). "Clinical and serum level monitoring in lithium therapy and lithium intoxication". J. Anal. Toxicol. 2: 193–202. doi:10.1093/jat/2.5.193.
- R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 851–854.
- The UK Electronic Medical Compendium recommends 0.4–0.8 mmol/l plasma lithium level in adults for prophylaxis of recurrent affective bipolar manic-depressive illness Camcolit 250 mg Lithium Carbonate Revision 2 December 2010, Retrieved 5 May 2011
- One study (Solomon, D.; Ristow, W.; Keller, M.; Kane, J.; Gelenberg, A.; Rosenbaum, J.; Warshaw, M. (1996). "Serum lithium levels and psychosocial function in patients with bipolar I disorder". The American Journal of Psychiatry 153 (10): 1301–1307. PMID 8831438.) concluded a "low" dose of 0.4–0.6 mmol/L serum lithium treatment for patients with bipolar 1 disorder had less side effects, but a higher rate of relapse, than a "standard" dose of 0.8–1.0 mmol/l. However, a reanalysis of the same experimental data (Perlis, R.; Sachs, G.; Lafer, B.; Otto, M.; Faraone, S.; Kane, J.; Rosenbaum, J. (2002). "Effect of abrupt change from standard to low serum levels of lithium: A reanalysis of double-blind lithium maintenance data". The American Journal of Psychiatry 159 (7): 1155–1159. PMID 12091193.) concluded the higher rate of relapse for the "low" dose was due to abrupt changes in the lithium serum levels[improper synthesis?]
- Australian Medicines Handbook. Adelaide: Australian Medicines Handbook Pty Ltd. 2013. ISBN 9780980579086.
- Joint Formulary Committee (2013). British National Formulary (BNF) 65. London: Pharmaceutical Press. pp. 240–242. ISBN 9780857110848.
- "lithium (Rx) - Eskalith, Lithobid". Medscape. WebMD. Retrieved 7 October 2013.
- "LITHOBID (lithium carbonate) tablet, film coated, extended release [NOVEN THERAPEUTICS, LLC]". DailyMed. National Library of Medicine. Retrieved 7 October 2013.
- "PRODUCT INFORMATION LITHICARB Lithium carbonate". TGA eBusiness Services. Aspen Pharmacare Australia Pty Ltd. Retrieved 7 October 2013.
- Safe and effective use of lithium Australian Prescriber
- Sperner-Unterweger, Barbara; W. Wolfgang Fleischhacker, Wolfgang P. Kaschka (2001). Psychoneuroimmunology. Karger Publishers. p. 22. ISBN 3-8055-7262-X.
- Wetzels, JF; Van Bergeijk, JD; Hoitsma, AJ; Huysmans, FT; Koene, RA (1989). "Triamterene increases lithium excretion in healthy subjects: Evidence for lithium transport in the cortical collecting tubule". Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 4 (11): 939–42. PMID 2516883.
- Keshavan, Matcheri S.; John S. Kennedy (2001). Drug-induced dysfunction in psychiatry. Taylor & Francis. p. 305. ISBN 0-89116-961-X.
- Side Effects – Lithium / Various Brand Names – Bipolar Disorder Medications
- Bipolar Medications and Weight Gain
- Nutrition Articles – The Relationship between Weight Gain and Medications for Depression and Seizures
- Safer lithium therapy. NHS National Patient Safety Agency. Issue date: 1 December 2009
- Bendz, Hans; Schön, Attman, Aurell (1 February 2010). "Renal failure occurs in chronic lithium treatment but is uncommon". Kidney International 77 (3): 219–24. doi:10.1038/ki.2009.433. PMID 19940841.
- Lee, Michael S.; Lessell, Simmons (28 January 2003). "Lithium-induced periodic alternating nystagmus". Neurology (journal) 60 (2): 344. doi:10.1212/01.WNL.0000042787.51461.D1. PMID 12552061.
- Williams, Douglas P.; Jack Rogers and B. Todd Troost (September 1988). "Lithium-Induced Downbeat Nystagmus". Archives of Neurology 45 (9): 1022–1023. doi:10.1001/archneur.1988.00520330112019. PMID 3137915.
- Shepard, TH.; Brent, RL.; Friedman, JM.; Jones, KL.; Miller, RK.; Moore, CA.; Polifka, JE. (2002). "Update on new developments in the study of human teratogens". Teratology 65 (4): 153–61. doi:10.1002/tera.10032. PMID 11948561.
- Yacobi, S; Ornoy, A (2008). "Is lithium a real teratogen? What can we conclude from the prospective versus retrospective studies? A review". The Israel journal of psychiatry and related sciences 45 (2): 95–106. PMID 18982835.
- Montouris, G (2003). "Gabapentin exposure in human pregnancy: Results from the Gabapentin Pregnancy Registry". Epilepsy & behavior : E&B 4 (3): 310–7. doi:10.1016/S1525-5050(03)00110-0. PMID 12791334.
- Weinstock, L; Cohen, LS; Bailey, JW; Blatman, R; Rosenbaum, JF (2001). "Obstetrical and neonatal outcome following clonazepam use during pregnancy: A case series". Psychotherapy and psychosomatics 70 (3): 158–62. doi:10.1159/000056242. PMID 11340418.
- Boyer, EW. "Serotonin syndrome". UpToDate. Wolters Kluwer. Retrieved 8 October 2013.
- Wijdicks, EFM. "Neuroleptic malignant syndrome". UpToDate. Wolters Kluwer. Retrieved 8 October 2013.
- Gelder, M., Mayou, R. and Geddes, J. 2005. Psychiatry. 3rd ed. New York: Oxford. pp249.
- Adityanjee; Munshi, Thampy (2005). "The syndrome of irreversible lithium-effectuated neurotoxicity.". Clinical Neuropharmacology 28 (1): 38–49. doi:10.1097/01.wnf.0000150871.52253.b7. PMID 15714160.
- Brunton L, Chabner B, Knollman B. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, Twelfth Edition. McGraw Hill Professional; 2010.
- Jope RS (1999). "Anti-bipolar therapy: mechanism of action of lithium". Mol. Psychiatry 4 (2): 117–128. doi:10.1038/sj.mp.4000494. PMID 10208444.
- Lenox RH, Wang L (February 2003). "Molecular basis of lithium action: integration of lithium-responsive signaling and gene expression networks". Mol. Psychiatry 8 (2): 135–44. doi:10.1038/sj.mp.4001306. PMID 12610644.
- Massot, O.; Rousselle, J. C.; Fillion, M. P.; Januel, D.; Plantefol, M.; Fillion, G. (1999). "5-HT1B Receptors: A Novel Target for Lithium Possible Involvement in Mood Disorders". Neuropsychopharmacology 21 (4): 530–541. doi:10.1016/S0893-133X(99)00042-1. PMID 10481837.
- Scheuch, K.; Höltje, M.; Budde, H.; Lautenschlager, M.; Heinz, A.; Ahnert-Hilger, G.; Priller, J. (2010). "Lithium modulates tryptophan hydroxylase 2 gene expression and serotonin release in primary cultures of serotonergic raphe neurons". Brain Research 1307: 14–21. doi:10.1016/j.brainres.2009.10.027. PMID 19840776.
- Klein PS, Melton DA (August 1996). "A molecular mechanism for the effect of lithium on development". Proc. Natl. Acad. Sci. U.S.A. 93 (16): 8455–9. doi:10.1073/pnas.93.16.8455. PMC 38692. PMID 8710892.
- Yin L, Wang J, Klein PS, Lazar MA (February 2006). "Nuclear receptor Rev-erbalpha is a critical lithium-sensitive component of the circadian clock". Science 311 (5763): 1002–5. doi:10.1126/science.1121613. PMID 16484495. Lay summary – The Scientist.
- York JD et al. (1995) "Definition of a metal-dependent/Li+-inhibited phosphomonoesterase protein family based upon a conserved three-dimensional core structure". Proc. Natl. Acad. Sci. U.S.A. 92, 5149-5153
- Yenush Let al. (2000) "A novel target of lithium therapy". FEBS Lett. 467, 321-325
- Toledano E et al. "3'-5' phosphoadenosine phosphate is an inhibitor of PARP-1 and a potential mediator of the lithium-dependent inhibition of PARP-1 in vivo". Biochem J. 2012 443(2):485-90. 
- Ghasemi M, Sadeghipour H, Mosleh A, Sadeghipour HR, Mani AR, Dehpour AR (May 2008). "Nitric oxide involvement in the antidepressant-like effects of acute lithium administration in the mouse forced swimming test". Eur Neuropsychopharmacol 18 (5): 323–32. doi:10.1016/j.euroneuro.2007.07.011. PMID 17728109.
- Ghasemi M, Sadeghipour H, Poorheidari G, Dehpour AR (June 2009). "A role for nitrergic system in the antidepressant-like effects of chronic lithium treatment in the mouse forced swimming test". Behav. Brain Res. 200 (1): 76–82. doi:10.1016/j.bbr.2008.12.032. PMID 19166880.
- Ghasemi M, Raza M, Dehpour AR (April 2010). "NMDA receptor antagonists augment antidepressant-like effects of lithium in the mouse forced swimming test". J. Psychopharmacol. (Oxford) 24 (4): 585–94. doi:10.1177/0269881109104845. PMID 19351802.
- Einat H, Kofman O, Itkin O, Lewitan RJ, Belmaker RH (1998). "Augmentation of lithium's behavioral effect by inositol uptake inhibitors". J Neural Transm 105 (1): 31–8. doi:10.1007/s007020050035. PMID 9588758.
- Marmol, F. (2008). "Lithium: Bipolar disorder and neurodegenerative diseases Possible cellular mechanisms of the therapeutic effects of lithium". Progress in Neuro-Psychopharmacology and Biological Psychiatry 32 (8): 1761–1771. doi:10.1016/j.pnpbp.2008.08.012. PMID 18789369.
- Lenox, RH; Watson, DG (1994). "Lithium and the brain: a psychopharmacological strategy to a molecular basis for manic depressive illness". Clinical chemistry 40 (2): 309–14. PMID 8313612.
- Mitchell, PB; Hadzi-Pavlovic, D (2000). "Lithium treatment for bipolar disorder". Bulletin of the World Health Organization 78 (4): 515–7. PMC 2560742. PMID 10885179.
- Greenfield, Susan: "Brain Power: Working out the Human Mind", page 91. Element Books Limited, 1999
- Shorter, E. (2009). The history of lithium therapy. Bipolar Disorders, 11, 4–9. doi:10.1111/j.1399-5618.2009.00706.x
- Cade J. F. J. (1949). "Lithium salts in the treatment of psychotic excitement" (PDF). Medical Journal of Australia 2 (10dfbnm): 349–52. PMID 18142718.
- P. B. Mitchell, D. Hadzi-Pavlovic (2000). "Lithium treatment for bipolar disorder" (PDF). Bulletin of the World Health Organization 78 (4): 515–7. PMC 2560742. PMID 10885179.
- Agassi, Tirzah (1996-03-12). "Sting is now older, wiser and duller". The Jerusalem Post. Retrieved 2009-06-25.
- "7 UP: The Making of a Legend". Cadbury Schweppes: America's Beverages.
- "Urban Legends Reference Pages: 7Up". Retrieved 13 November 2007.
- anonymous (13 July 1950). "ISALLY'S (ad)". Painesville Telegraph. Retrieved 8 September 2013.
- Forlenza, OV; de Paula, VJ; Machado-Vieira, R; Diniz, BS; Gattaz, WF (1 May 2012). "Does lithium prevent Alzheimer's disease?". Drugs & aging 29 (5): 335–42. doi:10.2165/11599180-000000000-00000. PMID 22500970.
- Ludolph, AC; Brettschneider, J; Weishaupt, JH (October 2012). "Amyotrophic lateral sclerosis.". Current opinion in neurology 25 (5): 530–5. doi:10.1097/WCO.0b013e328356d328. PMID 22918486.
- Official FDA information published by Drugs.com
- "Exposing lithium's circadian action"
- CID 11125 — PubChem Compound Summary (Lithium Carbonate)